Literature DB >> 20979472

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

James E Butrynski1, David R D'Adamo, Jason L Hornick, Paola Dal Cin, Cristina R Antonescu, Suresh C Jhanwar, Marc Ladanyi, Marzia Capelletti, Scott J Rodig, Nikhil Ramaiya, Eunice L Kwak, Jeffrey W Clark, Keith D Wilner, James G Christensen, Pasi A Jänne, Robert G Maki, George D Demetri, Geoffrey I Shapiro.   

Abstract

Inflammatory myofibroblastic tumor (IMT) is a distinctive mesenchymal neoplasm characterized by a spindle-cell proliferation with an inflammatory infiltrate. Approximately half of IMTs carry rearrangements of the anaplastic lymphoma kinase (ALK) locus on chromosome 2p23, causing aberrant ALK expression. We report a sustained partial response to the ALK inhibitor crizotinib (PF-02341066, Pfizer) in a patient with ALK-translocated IMT, as compared with no observed activity in another patient without the ALK translocation. These results support the dependence of ALK-rearranged tumors on ALK-mediated signaling and suggest a therapeutic strategy for genomically identified patients with the aggressive form of this soft-tissue tumor. (Funded by Pfizer and others; ClinicalTrials.gov number, NCT00585195.).

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20979472      PMCID： PMC3014292          DOI： 10.1056/NEJMoa1007056

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


  24 in total

1.  Inflammatory myofibroblastic tumor (plasma cell granuloma). Clinicopathologic study of 20 cases with immunohistochemical and ultrastructural observations.

Authors:  G Pettinato; J C Manivel; N De Rosa; L P Dehner
Journal:  Am J Clin Pathol       Date:  1990-11       Impact factor: 2.493

2.  Recurrent involvement of 2p23 in inflammatory myofibroblastic tumors.

Authors:  C A Griffin; A L Hawkins; C Dvorak; C Henkle; T Ellingham; E J Perlman
Journal:  Cancer Res       Date:  1999-06-15       Impact factor: 12.701

3.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.

Authors:  Brian J Druker; François Guilhot; Stephen G O'Brien; Insa Gathmann; Hagop Kantarjian; Norbert Gattermann; Michael W N Deininger; Richard T Silver; John M Goldman; Richard M Stone; Francisco Cervantes; Andreas Hochhaus; Bayard L Powell; Janice L Gabrilove; Philippe Rousselot; Josy Reiffers; Jan J Cornelissen; Timothy Hughes; Hermine Agis; Thomas Fischer; Gregor Verhoef; John Shepherd; Giuseppe Saglio; Alois Gratwohl; Johan L Nielsen; Jerald P Radich; Bengt Simonsson; Kerry Taylor; Michele Baccarani; Charlene So; Laurie Letvak; Richard A Larson
Journal:  N Engl J Med       Date:  2006-12-07       Impact factor: 91.245

4.  Successful preoperative treatment of pediatric bladder inflammatory myofibroblastic tumor with anti-inflammatory therapy.

Authors:  Alisa Berger; Christina Kim; Nathan Hagstrom; Fernando Ferrer
Journal:  Urology       Date:  2007-08       Impact factor: 2.649

5.  Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy.

Authors:  Sylvie Giuriato; Nathalie Faumont; Emilie Bousquet; Marianne Foisseau; Anne Bibonne; Marc Moreau; Talal Al Saati; Dean W Felsher; Georges Delsol; Fabienne Meggetto
Journal:  Cancer Biol Ther       Date:  2007-05-29       Impact factor: 4.742

6.  Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Authors:  Manabu Soda; Young Lim Choi; Munehiro Enomoto; Shuji Takada; Yoshihiro Yamashita; Shunpei Ishikawa; Shin-ichiro Fujiwara; Hideki Watanabe; Kentaro Kurashina; Hisashi Hatanaka; Masashi Bando; Shoji Ohno; Yuichi Ishikawa; Hiroyuki Aburatani; Toshiro Niki; Yasunori Sohara; Yukihiko Sugiyama; Hiroyuki Mano
Journal:  Nature       Date:  2007-07-11       Impact factor: 49.962

7.  Inflammatory myofibroblastic tumor: comparison of clinicopathologic, histologic, and immunohistochemical features including ALK expression in atypical and aggressive cases.

Authors:  Cheryl M Coffin; Jason L Hornick; Christopher D M Fletcher
Journal:  Am J Surg Pathol       Date:  2007-04       Impact factor: 6.394

Review 8.  Inflammatory myofibroblastic tumours: where are we now?

Authors:  B C Gleason; J L Hornick
Journal:  J Clin Pathol       Date:  2007-10-15       Impact factor: 3.411

9.  Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.

Authors:  James G Christensen; Helen Y Zou; Maria E Arango; Qiuhua Li; Joseph H Lee; Scott R McDonnell; Shinji Yamazaki; Gordon R Alton; Barbara Mroczkowski; Gerrit Los
Journal:  Mol Cancer Ther       Date:  2007-12       Impact factor: 6.261

10.  Inflammatory fibrosarcoma of the mesentery and retroperitoneum. A tumor closely simulating inflammatory pseudotumor.

Authors:  J M Meis; F M Enzinger
Journal:  Am J Surg Pathol       Date:  1991-12       Impact factor: 6.394
View more
  254 in total

1.  Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

Authors:  Alice T Shaw; Beow Y Yeap; Benjamin J Solomon; Gregory J Riely; Justin Gainor; Jeffrey A Engelman; Geoffrey I Shapiro; Daniel B Costa; Sai-Hong I Ou; Mohit Butaney; Ravi Salgia; Robert G Maki; Marileila Varella-Garcia; Robert C Doebele; Yung-Jue Bang; Kimary Kulig; Paulina Selaru; Yiyun Tang; Keith D Wilner; Eunice L Kwak; Jeffrey W Clark; A John Iafrate; D Ross Camidge
Journal:  Lancet Oncol       Date:  2011-09-18       Impact factor: 41.316

Review 2.  Quantifying factors for the success of stratified medicine.

Authors:  Mark R Trusheim; Breon Burgess; Sean Xinghua Hu; Theresa Long; Steven D Averbuch; Aiden A Flynn; Alfons Lieftucht; Abhijit Mazumder; Judy Milloy; Peter M Shaw; David Swank; Jian Wang; Ernst R Berndt; Federico Goodsaid; Michael C Palmer
Journal:  Nat Rev Drug Discov       Date:  2011-10-31       Impact factor: 84.694

3.  Trial watch: success for crizotinib in ALK-driven cancer.

Authors: 
Journal:  Nat Rev Drug Discov       Date:  2010-12       Impact factor: 84.694

4.  ALK and resistance.

Authors: 
Journal:  Nat Rev Cancer       Date:  2010-12       Impact factor: 60.716

Review 5.  ALK-positive large B-cell lymphoma: identification of EML4-ALK and a review of the literature focusing on the ALK immunohistochemical staining pattern.

Authors:  Kana Sakamoto; Hideki Nakasone; Yuki Togashi; Seiji Sakata; Naoko Tsuyama; Satoko Baba; Akito Dobashi; Reimi Asaka; Chien-Chen Tsai; Shih-Sung Chuang; Koji Izutsu; Yoshinobu Kanda; Kengo Takeuchi
Journal:  Int J Hematol       Date:  2016-01-18       Impact factor: 2.490

6.  Entrectinib in Two Pediatric Patients With Inflammatory Myofibroblastic Tumors Harboring ROS1 or ALK Gene Fusions.

Authors:  Srikanth R Ambati; Emily K Slotkin; Edna Chow-Maneval; Ellen M Basu
Journal:  JCO Precis Oncol       Date:  2018-09-13

Review 7.  Anaplastic Lymphoma Kinase as a Therapeutic Target in Non-Small Cell Lung Cancer.

Authors:  Wade T Iams; Christine M Lovly
Journal:  Cancer J       Date:  2015 Sep-Oct       Impact factor: 3.360

Review 8.  Inflammatory stress and sarcomagenesis: a vicious interplay.

Authors:  Jürgen Radons
Journal:  Cell Stress Chaperones       Date:  2013-08-27       Impact factor: 3.667

9.  Partial response to chemotherapy in a patient with retroperitoneal inflammatory myofibroblastic tumor.

Authors:  Ming Chen; Lihua Zhang; Guochun Cao; Weidong Zhu; Xuqiu Chen; Quan Fang
Journal:  Mol Clin Oncol       Date:  2016-07-27

Review 10.  Children's Oncology Group's 2013 blueprint for research: Soft tissue sarcomas.

Authors:  Douglas S Hawkins; Sheri L Spunt; Stephen X Skapek
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.